Profibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders
|
|
- Ferdinand Lawrence
- 6 years ago
- Views:
Transcription
1 ProFiDIΛ Profibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders THROMBOLYSIS WITH IMPROVED SAFETY A valorisation project of
2 Unmet Medical Need = Safe Thrombolysis 1 out of 4 deaths due to cardiovascular thrombosis N 1 Acute coronary syndromes N 2 Stroke N 3 Pulmonary embolism Significant innovation in mechanical thrombectomy, but not in pharmacological strategies for clot lysis Risk of bleeding precludes the use of plasminogen activators in the patients with stroke and pulmonary embolism
3 Opportunities for thrombolytics with improved safety profile Indications Standard-of-Care Limitations Unmet Needs Acute Ischemic Stroke Thrombectomy preferred (40% of the patients) Thrombectomy not always available Patients not eligible (time, small artery occlusion) Priming the thrombotic occlusion prior to thrombectomy with a safe profibrinolytic agent (with or without low dose of tpa) Thrombolysis for patients not eligible for thrombectomy (60% of the patients) Narrow time window for thrombolysis Bleeding risk (ICH) tpa induced neurotoxicity Improved safety (less ICH) Longer time window Treatment for patients not eligible for thrombectomy and/or thrombolysis with current agents Pulmonary thromboembolism Thrombolysis (shown to reduce cardiovascular collapse) Bleeding risk (ICH) Reduce residual clot burden Improved safety Preventing right ventricular failure in patients Decrease risk of recurrence
4 Dual TAFI/PAI-1 inhibition improves the efficacy of endogenous tpa
5 Parental antibody generation Antibody (150 kda) Heavy chain Light chain Antibody (150 kda) Heavy chain Light chain CL CH 1 CH 1 CL CL CH 1 CH 1 CL CH 2 CH 2 CH 2 CH 2 CH 3 anti-pai-1 Mab anti-tafi Mab MA-33H1F7 CH 3 CH 3 CH 3 MA-TCK26D6 MA-33H1F7 was raised by immunizing PAI-1 knock-out mice with the human PAI- 1/tPA complex. MA-33H1F7 crossreacts and binds murine PAI-1 with almost a similar degree. MA-33H1F7 neutralizes murine PAI-1 to a similar extent as human PAI-1. MA-33H1F7 does not inhibit vitronectinbound PAI-1 MA-TCK26D6 was raised by immunizing TAFI knock-out mice with human TAFI. MA-TCK26D6 binds both human and mouse TAFI with a similar affinity. MA-TCK26D6 does not inhibit Thrombin/Thrombomodulin activation of TAFI
6 Diabody construction Antibody (150 kda) Heavy chain Light chain Antibody (150 kda) Heavy chain Light chain CL CH 1 CH 1 CL CL CH 1 CH 1 CL CH 2 CH 2 CH 2 CH 2 anti-tafi Mab anti-pai-1 Mab MA-TCK26D6 CH 3 CH 3 CH 3 CH 3 MA-33H1F7 A A Anti-TAFI 9 AA linker Anti-TAFI scfv (28 kda) Anti-PAI-1 B B Anti-PAI-1 scfv (28 kda) Diabody (58 kda)
7 Resistence (mm) Strong in vitro profibrinolytic properties In a thromboelastometric assay, we confirmed that simultaneous inhibition of TAFI and PAI-1 causes an enhancement of in vitro fibrinolysis in human blood Citrated whole blood + MA(s), diabody or saline 10, 37 C + CaCl 2 + Tissue factor + tpa Anti-PAI-1 MA Anti-TAFI MA Combination of MA Time (min) 7 Diabody
8 Strong in vitro profibrinolytic properties HUMAN BLOOD Full lysis P < 0.05 Paired t-test L45 (%) *** *** 20 0 MA-33H1F7 MA-TCK26D6 Combination of antibodies Diabody N = 4 *** P < Kruskal-Wallis test No lysis
9 Strong in vivo profibrinolytic properties Monofilament-mediated stroke model 1 hour 24 hours MCAo 1. Reperfusion 2. Treatment 100 * Fibrin deposition Infarct size Neurological test Motor test Berressem Nutritionalneuroscience.com N =10-12/ group * P < 0.05 Lesion volume (mm 3 ) Vehicle Control IgG (2 mg/kg) MA-33H1F7 (1 mg/kg) MA-TCK26D6 (1 mg/kg) combination of MA Diabody (0.8 mg/kg) Vehicle Diabody (0.8mg/kg)
10 Diabody vs tpa Thrombotic middle cerebral artery occlusion models FeCl 3 Thrombin pipette MCA MCA MCA MCA Karatas et al. Stroke 2011 Orset et al. Stroke 2007 FeCl 3 Thrombin Oxidative stress Platelet activation Fibrinogen Fibrin Collaboration with prof. Denis Vivien and Dr. Marina Rubio INSERM, France
11 Diabody vs tpa Thrombotic middle cerebral artery occlusion models FeCl 3 Thrombin pipette MCA MCA MCA MCA Karatas et al. Stroke 2011 Orset et al. Stroke 2007 Platelet-rich clot Fibrin-rich clot Resistant to tpa-mediated lysis Susceptible to tpa-mediated lysis Collaboration with prof. Denis Vivien and Dr. Marina Rubio INSERM, France
12 Improved efficacy compared to tpa on platelet rich clots Thrombotic middle cerebral artery occlusion models hours MCAo Platelet-rich clot Db or Buffer tpa or Buffer 1. Arterial status 2. Lesion size 3. Brain perfusion Vehicle 25 * tpa Db Infarct volume (mm 3 ) 24h post stroke onset * P < 0.05 N = 9-15/ group 0 Db 2x 12 vehicle tpa 10mg/kg Db 1.6mg/kg Db 3.6mg/kg
13 Improved efficacy compared to tpa on fibrin rich clots Thrombotic middle cerebral artery occlusion models hours MCAo Fibrin-rich clot Db or Buffer tpa or Buffer 1. Arterial status 2. Lesion size 3. Brain perfusion
14 Improved safety compared to tpa Tail vein bleeding model in mice: tpa increases hemoglobin loss, whereas the diabody does not
15 Summary Db-TCK26D6x33H1F7 has strong profibrinolytic properties in vitro and in vivo: - More effective than the combined addition of antibodies - More effective in lysing a thrombus than tpa - Beneficial effect in thrombo-embolism model and in all MCAo models tested - No increased tail bleeding times Db-TCK26D6x33H1F7 accumulates in the thrombus Db-TCK26D6x33H1F7 has a circulating half-life of 121 min in mice (tpa = 5 min)
16 ProFiDIA development plan Antibody discovery and diabody generation Diabody optimization Candidate selection Non clinical development Phase 1 Phase 2a Phase 2b/3 Antibody screening Antibody engineering In vitro testing In vivo POC efficacy Humanization Optimizing antigen binding potency, expression, stability and biophysical properties In vivo POC efficacy Extensive testing of humanized diabody in preclinical models t-pa comparison studies Bleeding studies PK/PD relationship CMC Scale-up, process & analytical development Non-clinical batch development Non clinical studies Safety pharmacology (mice, cynomolgus) Single/2 week dose toxicity in mice 2 week dose toxicity in cynemolgus Human TCR CMC Clinical batch production Clinical study Dose escalation Dose finding Drug-drug interaction study CMC Clinical batch production Clinical study Feasibility POC efficacy study in stroke patients Partnering Clinical studies Elaborated POC efficacy studies Achieved Ongoing Development within ProFiDIA Partnering M1: Candidate May 2017 M2: IND application Nov 2018 M3: Safe dose in human Sep 2019 M4: Clinical POC Dec 2020
17 IP & FTO IP o DUAL TARGETING OF TAFI AND PAI-1 (US 61/ & PCT/EP2015/052624): Priority date 07/02/2014; Use claims alone or in combination with tpa for treatment of acute thrombotic disorders Composition claims o Claims approved for N, IS and IA; entering national phase 08/2016 FTO o o To our knowledge, no other groups have applied for patent protection for a bispecific antibody that targets both PAI-1 and TAFI. No hits were identified in keyword searches conducted in Jan 2014, prior to filing the earliest priority patent application, in a commercial patent database (Thomson Innovation).
18 Conclusion The ProFiDIA diabody is a first-in class fibrinolysis enhancer for treatment of stroke and submassive PE The ProFiDIA diabody is protected by granted patent (national phase aug/sept 2016) The (non) clinical development roadmap is feasible
19 ProFiDIΛ Profibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders THROMBOLYSIS WITH IMPROVED SAFETY
Bispecific inhibi,on of. Thrombin Ac,vatable Fibrinolysis Inhibitor (TAFI) and Plasminogen Ac,vator Inhibitor - 1 (PAI- 1) as a fibrinoly,c enhancer
Bispecific inhibi,on of Thrombin Ac,vatable Fibrinolysis Inhibitor (TAFI) and Plasminogen Ac,vator Inhibitor - 1 (PAI- 1) as a fibrinoly,c enhancer Wyseure T, Vercauteren E, Gils A and Declerck PJ Laboratory
More informationCM-352: a new, potent and safe molecule for the prevention and treatment of haemorrhage
XIV Encuentro de Cooperación Farma-Biotech CM-352: a new, potent and safe molecule for the prevention and treatment of haemorrhage Madrid, 17 de noviembre de 2015 Outline Institution: CIMA Project Partnering
More informationPotential for better thrombolytic therapy with Plasmin a novel plasma product. Valery Novokhatny
Potential for better thrombolytic therapy with Plasmin a novel plasma product Valery Novokhatny Plasmin Basics Diseases of Thrombosis Clot formation in blood vessels represent the mechanism of mortality
More informationROZAIMAH ZAIN-HAMID. Department of Pharmacology and Therapeutics Faculty of Medicine, Universitas Sumatera Utara
ROZAIMAH ZAIN-HAMID Department of Pharmacology and Therapeutics Faculty of Medicine, Universitas Sumatera Utara Drugs Used in Disorders of Coagulation Fibrinolytic drugs Anti-thrombotic thrombotic drugs
More informationSupplement Figure 1. Characterization of the moab. (A) A series of moabs that are anti-hαiib-specific were tested for their ability to bind to
Supplement Figure 1. Characterization of the 312.8 moab. (A) A series of moabs that are anti-hαiib-specific were tested for their ability to bind to platelets. The black line represents the 312.8 moab
More informationIV tpa: 1996 to Present
IV tpa: 1996 to Present Where We ve Come From & What We ve Learned 1 Many of the things that seem impossible now will become realities of tomorrow. 2 Streptococcus Discovered back in the 1930s Activates
More informationChanges in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase
Clinical Hemorheology and Microcirculation 23 (2000) 213 218 213 IOS Press Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase Lirong Jin
More informationUvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication
UvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication Citation for published version (APA): van Montfoort, M. L. (2014). Factor XI
More informationPlatelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.
Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin
More informationThe European Stroke Network
The European Stroke Network A Unique Alliance for Combating Stroke Prof. Dr. Stephen Meairs Department of Neurology University Medicine Mannheim University of Heidelberg, Germany European Stroke Network
More informationLina Al-Lawama. Rama Al-Ashqar. Malik Al-Zohlof
2 Lina Al-Lawama Rama Al-Ashqar Malik Al-Zohlof Anticoagulant drugs Recap Last lecture we were talking about antiplatelet drugs, we mentioned 5 drugs : Aspirin which is used alone with patents that have
More informationASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS
ASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS Jean AMIRAL, President HYPHEN BioMed (France) Fibrinolysis Functions Neurology (brain) Fertility Cell Remodelling FIBRINOLYSIS Malignancy (metastasis)
More informationTHE EFFECT OF ULTRASOUND ON THROMBOLYSIS: The rationale for EKOS Acoustic Pulse Thrombolysis Therapy
THE EFFECT OF ULTRASOUND ON THROMBOLYSIS: The rationale for EKOS Acoustic Pulse Thrombolysis Therapy INTRODUCTION A small number of recent clinical studies have focused discussion on the efficacy of ultrasound
More informationPharmacology Lecture 5. Anticoagulants
Pharmacology Lecture 5 Anticoagulants General overview Anti-thrombotic Drugs Antiplatlets Anticoagulants Fibrinolytics Anticoagulants Indirect Thrombin Inhibitors Anti-thrombotic effect is exerted by interaction
More informationRat Tissue-type Plasminogen Activator (tpa) Total Antigen ELISA
Package Insert Rat Tissue-type Plasminogen Activator (tpa) Total Antigen ELISA 96 Wells For Research Use Only v. 1.0 Eagle Biosciences, Inc. 20A NW Blvd., Suite 112, Nashua, NH 03063 Phone: 866-419-2019
More informationVampire Bat Plasminogen Activator DSPA-Alpha-1 (Desmoteplase): A Thrombolytic Drug Optimized by Natural Selection
Fibrinolysis Haemostasis 2001;31:118 122 Vampire Bat Plasminogen Activator DSPA-Alpha-1 (Desmoteplase): A Thrombolytic Drug Optimized by Natural Selection Wolf-Dieter Schleuning Paion GmbH, Research Center
More informationISIS PHARMACEUTICALS. ISIS-FXI Rx Program Update. Webcast December 8, 2014
ISIS PHARMACEUTICALS ISIS-FXI Rx Program Update Webcast December 8, 2014 Introduction Stan Crooke, M.D., Ph.D. CEO and Chairman, Isis Pharmaceuticals 2 Forward Looking Language Statement This presentation
More informationImmunogenicity Assay Strategies for Antibody-Drug Conjugates
Immunogenicity Assay Strategies for Antibody-Drug Conjugates 8th World ADC Conference, San Diego 20 Sep 2017 Seema Kumar, PhD Associate Scientific Director Global Early Development (GED) EMD Serono Research
More informationKILLING THROMBUS WITH
KILLING THROMBUS WITH D. Dash Department of Biochemistry Institute of Medical Sciences Banaras Hindu University Thrombus has two components: (1) Protein Component composed of Insoluble Fibrin Clot (2)
More informationBiologic Drug Delivery Across the Blood-Brain Barrier with IgG Fusion Proteins. William M. Pardridge, M.D. University of California ArmaGen, Inc.
Biologic Drug Delivery Across the Blood-Brain Barrier with IgG Fusion Proteins William M. Pardridge, M.D. University of California ArmaGen, Inc. 1 The Brain and Biotechnology In 2017, there are no biologics
More informationAdvanced Therapeutic Antibody Discovery with Multiplexed Screening
Advanced Therapeutic Antibody Discovery with Multiplexed Screening White Paper Scientists need powerful tools that can deliver results to fully understand the ability of candidate antibodies to interrupt
More informationEDUCATIONAL COMMENTARY D-DIMER UPDATE
EDUCATIONAL COMMENTARY D-DIMER UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing
More informationManaging the Risks Associated with Anticoagulant Therapy. Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde
Managing the Risks Associated with Anticoagulant Therapy Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde Background Identified as high risk medicines Wide range
More informationBayer R&D Investor Day 2005
Science For A Better Life HealthCare Bayer R&D Investor 25 December 8, 25 London Bayer R&D Investor 25 BAY 59-7939: A Novel, ral, Direct Factor Xa Inhibitor Frank Misselwitz Head of Therapeutic Area Cardiovascular,
More informationThe Nanobody ALX-0681 is Efficacious and Safe in a Baboon Model of Acquired TTP
The Nanobody ALX-0681 is Efficacious and Safe in a Baboon Model of Acquired TTP Filip Callewaert, Jan Roodt, Hans Ulrichts, Thomas Stohr, Walter Janse van Rensburg, Seb Lamprecht, Stefaan Rossenu, Sofie
More informationProteoGenix. Life Sciences Services and Products. From gene to biotherapeutics Target Validation to Lead optimisation
ProteoGenix Life Sciences Services and Products From gene to biotherapeutics Target Validation to Lead optimisation ProteoGenix Philippe FUNFROCK, founder and CEO French company located in Strasbourg,
More informationWhy Knowledge of Translational PK/PD at Sites of Action Are Important to Optimize Bispecific Antibody Development?
Why Knowledge of Translational PK/PD at Sites of Action Are Important to Optimize Bispecific Antibody Development? Weirong Wang, Ph.D. Biologics Clinical Pharmacology Why Knowledge of Translational PK/PD
More informationAdv Pathophysiology Unit 4 Page 1 of 10. Learning Objectives for this file:
Adv Pathophysiology Unit 4 Page 1 of 10 Learning Objectives for this file: Topics include structure & function of: 1. Coagulation process platelets, clotting factors 2. Coagulation cascade formation of
More informationLinking in silico and in vitro experiments to identify and evaluate a biomarker for enoxaparin activity
Linking in silico and in vitro experiments to identify and evaluate a biomarker for enoxaparin activity Abhishek Gulati What is enoxaparin? Low molecular weight heparin anticoagulant Used to minimise the
More informationAddressing challenges of targeting the macrophage checkpoint, CD47. Marie Kosco-Vilbois, PhD CSO
Addressing challenges of targeting the macrophage checkpoint, CD47 Marie Kosco-Vilbois, PhD CSO 1 CD47 is an immune checkpoint Cancer cell Macrophage Activating eat me signal CD47 Inhibitory don t eat
More informationMembrane microvesicles: a circulating source for fibrinolysis, new antithrombotic
Membrane microvesicles: a circulating source for fibrinolysis, new antithrombotic messengers 1 Laurent Plawinski, 2,3 Eduardo Anglés-Cano 1 CNRS UMR 5248 Imagerie Moléculaire et Nanobiotechnologie, Université
More informationBivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide?
Bivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide? Vinod Nair MD FACC FSCAI Cardiovascular Ins6tute of the South, Houma Financial Disclosure:
More informationClinical and molecular determinants of arterial thrombus structure
Clinical and molecular determinants of arterial thrombus structure PhD thesis booklet András Kovács, MD Semmelweis University Doctoral School of Molecular Medicine Supervisor: Official reviewers: Krasimir
More informationDr. Susan Louw Haematopathologist NHLS / WITS / SASTH
Dr. Susan Louw Haematopathologist NHLS / WITS / SASTH Since 1948 Initially a research tool Utility in management of bleeding and thrombosis Guide clotting factor replacement, platelet / blood transfusions
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationControl Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design!
Control Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design! Marjorie Shapiro Office of Biotechnology Products/FDA WCBP 2017 January 25, 2017 Disclaimer The views presented
More informationRECRUIT-TandAbs: a versatile bispecific antibody platform designed for immune therapy of cancer. Eugene Zhukovsky
RECRUIT-TandAbs: a versatile bispecific antibody platform designed for immune therapy of cancer Eugene Zhukovsky 29th Monoclonal Antibodies Meeting, Mykonos 2012 Affimed s profile Affimed is a clinical
More informationPreclinical Development of Biologics: Case-by-case, so get off of my case!
Preclinical Development of Biologics: Case-by-case, so get off of my case! Northeast Chapter SOT David Jacobson-Kram, Ph.D., DABT Office of New Drugs Center for Drug Evaluation and Research FDA October
More informationOERMATAN SULFATE: A NEW CONCEPT IN ANTITHROMBOTIC THERAPY
OERMATAN SULFATE: A NEW CONCEPT IN ANTITHROMBOTIC THERAPY by JOANNE VAN RYN-McKENNA, B.Sc., M.Sc. A Thesis Submitted to the School of Graduate Studies in Partial Fulfilment of the Requirements for the
More informationNanobodies against difficult targets Tackling ion channels
Nanobodies against difficult targets Tackling ion channels Collaborations in Ion Channel Drug Discovery 19-20 th June 2014 Nanobodies - Inspired by nature Company highlights Corporate Drug discovery and
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationHypercoagulation. CP Conference 11/14/2006
Hypercoagulation CP Conference 11/14/2006 Overview Hypercoagulation: poorly understood phenomena No definite cause is identified in > 40% of cases Three major factors in thrombus formation (Rudolf Virchow,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationQuantitative And Spatial Optimization Of Therapeutic Fusion Proteins
Quantitative And Spatial Optimization Of Therapeutic Fusion Proteins Jeffrey Way, Ph.D. Senior Staff Scientist, Wyss Institute, HMS CEO, General Biologics, Inc. 1 Chimeric Activators Drug design and targeted
More informationCaplacizumab. Wholly-owned anti-vwf Nanobody
1 Caplacizumab Wholly-owned anti-vwf Nanobody First-in-class bivalent Nanobody with Orphan Drug Status and patent protection up to 2035 Developed for the treatment of acquired thrombotic thrombocytopenic
More informationSMART HEALTH PROJECT
SMART HEALTH PROJECT SEDICIDODICI srl is a biomedical company constituted by a consolidated management and scientific expert team, focused on the development of a NOVEL EX VIVO DIAGNOSTIC MICROFLUIDIC
More informationBuilding a deep immuno-oncology portfolio in less than a year. David Johnson, PhD PEGS Spring 2018
Building a deep immuno-oncology portfolio in less than a year David Johnson, PhD PEGS Spring 2018 Improving early development 15-20 years, >$billion for an innovative new drug Attrition rate Target discovery
More informationOral NT-KO-003 for the Treatment of Multiple Sclerosis
Oral for the Treatment of Multiple Sclerosis Madrid, 27 de noviembre de 2013 Content 1. The Company 2. The Product a) Target Indications b) Innovative mechanisms of action c) Differential features facing
More informationPRE-HOSPITAL AND PERIPROCEDURE NEUROPROTECTION: THE FAST AND THE FURIOUS. William J. Mack, MD, MS, FAANS, FAHA
PRE-HOSPITAL AND PERIPROCEDURE NEUROPROTECTION: THE FAST AND THE FURIOUS William J. Mack, MD, MS, FAANS, FAHA Associate Professor of Neurosurgery Neuroscience Graduate Program Zilkha Neurogenetic Institute
More informationCoagulopathy Case-2. Andy Nguyen, M.D. 2009
Coagulopathy Case-2 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 42 year-old man brought to the emergency room with severe burn. Patient was rescued by firemen in a serious fire. He had been found unconscious
More informationAffimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
FOR IMMEDIATE RELEASE Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated;
More informationLVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Pharmacy Retrospective Evaluation of Delayed Administration of Fondaparinux in Providing Comparable Safety and Efficacy Outcomes in Patients
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 19 March 2009 EMEA/CHMP/BMWP/118264/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR BIOLOGICAL
More informationInfectious Disease Programs:
Infectious Disease Programs: Valortim (MDX-133) Fully Human Anti-Anthrax Toxin MAb Candidate for Project BioShield Procurement Israel Lowy, M.D., Ph.D. Senior Director, Clinical Science and Infectious
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More informationNew Hope For Serious Infections
New Hope For Serious Infections Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning
More informationClinical Importance of fibrinolysis measurement
Clinical beta-testing of a newly developed point-of-care technology shows potential to drastically reduce the time and complexity required for Fibrinolytic Activity measurements. Dr. Krassen Dimitrov,
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationVenous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? New Chest Guidelines 2016
Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? Marlene Grenon, MD Associate Professor of Surgery University of California San Francisco UCSF Vascular Surgery Symposium
More informationICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008
European Medicines Agency October 2009 EMEA/CHMP/ICH/607698/2008 ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008 TRANSMISSION TO INTERESTED
More informationCharacterization of antithrombin-specific RNA aptamers for use in anticoagulant therapy
Characterization of antithrombin-specific RNA aptamers for use in anticoagulant therapy Yolanda M. Fortenberry, Ph.D. Hematology 2014 Conference Johns Hopkins University School of Medicine What are aptamers?
More informationAnti-cancer drug discovery: from bench to bedside
Anti-cancer drug discovery: from bench to bedside Christian BAILLY, Ph.D. christian.bailly@pierre-fabre.com Pierre Fabre CDMO October 2nd, 2015 1 Christian BAILLY - Montpellier, October 2 nd, 2015 MOLECULES
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationSYNOPSIS. Clinical Study Report for Study CV Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: SYNOPSIS Clinical Study
More informationIndex. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108
A Accuracy, 6, 7, 15, 46, 52, 53, 61, 75, 100, 143, 144, 149, 166, 176, 178 Acquired coagulation disorders, 111 115 Acquired platelet disorders, 99 108 ACT. See Activated clotting time (ACT) Activated
More informationSUPPLEMENTARY FIGURE 1
SUPPLEMENTRY FIGURE 1 C D E F G * Supplementary Fig. 1: Platelets from Pik3c2b mice exhibit normal function. () Expression of platelet-specific glycoproteins on the surface of platelets in whole blood
More informationThese handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) Draft
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 24 April 2008 EMEA/CHMP/BMWP/118264/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) Draft GUIDELINE
More informationNasdaq: MAXY UBS Global Life Sciences Conference Dr. Russell Howard, CEO
Nasdaq: MAXY 2007 UBS Global Life Sciences Conference Dr. Russell Howard, CEO September 25, 2007 Safe Harbor Statement Information in this presentation includes forward-looking statements that involve
More informationSession 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationAdditional results from the Phase III HERCULES study with caplacizumab in acquired thrombotic thrombocytopenic purpura (attp)
Nanobodies creating better medicines Additional results from the Phase III HERCULES study with caplacizumab in acquired thrombotic thrombocytopenic purpura (attp) Webcast 12 th December 2017 2 Additional
More informationCoagulation in perspective: Blood management. Objectives
Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.
More informationn Huang, X., Moreton, F., Kalladka, D., Cheripelli, B. K., Macisaac, R., Tait, R. C., and Muir, K. (2015) Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke. Stroke,
More informationAnticoagulation in VTE The Haematologist s Perspective. Dr. M.D. Maina FRCP Edin.
Anticoagulation in VTE The Haematologist s Perspective Dr. M.D. Maina FRCP Edin. Disclosures None The coagulation process that leads to haemostasis involves a complex set of reactions involving approximately
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationHaemostasis Antibodies
HAEMOSTASIS ANTIBODIES FROM CEDARLANE www.cedarlanelabs.com NEW! The study of haemostasis and thrombosis has become one of the most rapidly growing fields in medical research. An unprecedented amount of
More informationBevyxxa (betrixaban) NEW PRODUCT SLIDESHOW
Bevyxxa (betrixaban) NEW PRODUCT SLIDESHOW Introduction Brand name: Bevyxxa Generic name: Betrixaban Pharmacological class: Factor Xa inhibitor Strength and Formulation: 40mg, 80mg; caps Manufacturer:
More informationNovel Anti-coagulant Agents. David G Hovord BA MB BChir FRCA Clinical Assistant Professor University of Michigan
Novel Anti-coagulant Agents David G Hovord BA MB BChir FRCA Clinical Assistant Professor University of Michigan Objectives Provide an overview of the normal coagulation, including perioperative testing
More informationSupplementary material and methods
Inhibitory effect of caffeic acid on ADP-induced thrombus formation and platelet activation involves mitogen-activated protein kinases Yu Lu 1,2,3,#, Quan Li 3,4,#, Yu-Ying Liu 3,4, Kai Sun 3,4, Jing-Yu
More informationPerson responsible (Chair): Martine Jandrot-Perrus, Hans Deckmyn
NAME OF PROJECT: Measurement of platelet activation markers: usefulness, current practices, future. Subcommittee: Platelet physiology Person responsible (Chair): Martine Jandrot-Perrus, Hans Deckmyn Design:
More informationPre Pre-IND and Pre-IND Interactions for Cell and Gene Therapy Products
Pre Pre-IND and Pre-IND Interactions for Cell and Gene Therapy Products Theresa Chen, PhD Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT) Office of Tissues and Advanced Therapies (OTAT)
More informationPreclinical development for SSc indications NO COPY. a preclinical portfolio in a perfect world. Jörg Distler
Preclinical development for SSc indications a preclinical portfolio in a perfect world Jörg Distler Department of Internal Medicine 3 and Institute for Clinical Immunology University of Erlangen-Nuremberg
More informationHaemostasis Antibodies
HAEMOSTASIS ANTIBODIES FROM CEDARLANE www.cedarlanelabs.com NEW! The study of haemostasis and thrombosis has become one of the most rapidly growing fields in medical research. An unprecedented amount of
More informationStroke is a leading cause of death and disability in
Matrix Metalloproteinase-10 Effectively Reduces Infarct Size in Experimental Stroke by Enhancing Fibrinolysis via a Thrombin-Activatable Fibrinolysis Inhibitor Mediated Mechanism J. Orbe, PhD; J. Barrenetxe,
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationAntithrombosis Management for Pediatric VAD and Beyond
Antithrombosis Management for Pediatric VAD and Beyond Christina VanderPluym M.D. Director of Ventricular Assist Device and Cardiac Antithrombosis Program Boston Children s Hospital, USA Disclosures I
More informationEvaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic ITP in a Randomized Placebo- Controlled Phase 3 Study
Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic ITP in a Randomized Placebo- Controlled Phase 3 Study Plenary Session at ASH 2007 Presented by Terry B. Gernsheimer Madeleine Verhovsek
More informationNON CLINICAL EFFICACY & SAFETY PROFILE OF IPH4102, ANTI-KIR3DL2 MAB IN CTCL TCL MEETING, BOLOGNA APRIL 2015
NON CLINICAL EFFICACY & SAFETY PROFILE OF IPH4102, ANTI-KIR3DL2 MAB IN CTCL TCL MEETING, BOLOGNA APRIL 2015 KIR3DL2 & IPH4102 IN CTCL INTRODUCTION KIR3DL2, UNIQUE THERAPEUTIC TARGET IN CTCL Inhibitory
More informationJournal: Nature Medicine
Journal: Nature Medicine Article Title: Authors Corresponding Author: PAI-1 mediates the anti-angiogenic and pro-fibrinolytic effects of 16K prolactin Khalid Bajou, Stephanie Herkenne, Victor L. Thijssen,
More information06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND
Preclinical Support for Exploratory Phase I Clinical Trials Clive Joseph, DSRD Sandwich Overview Identify the most appropriate development paradigm - traditional vs alternative IND approach Confidence
More informationPOST-ISTH: Novità dal meeting di Toronto 2015 Piastrine: fisiopatologia. Erica De Candia Università Cattolica -Roma
POST-ISTH: Novità dal meeting di Toronto 2015 Piastrine: fisiopatologia Erica De Candia Università Cattolica -Roma Novità ISTH 2015: Piastrine: Fisiopatologia i) Alternative platelet function throughout
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationAdvancing the Frontiers of mab mixtures
Advancing the Frontiers of mab mixtures...unlocking the power of the immune system Symphogen Corporate Presentation June 216 Symphogen/1 Symphogen Overview Privately held company - 125 employees Headquarters
More informationHeparin-Induced Thrombocytopenia and New Anticoagulants
Heparin-Induced Thrombocytopenia and New Anticoagulants September 2004 Elizabeth M. Van Cott, MD Massachusetts General Hospital Boston MA College of American Pathologists 2004. Materials are used with
More informationPLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS
PLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS Louise Angell Lead Scientist 10th Biosimilars & Follow-On Biologics Congregation 9 th May 2017 Copyright @ 2017 Covance. All rights Reserved Overview
More informationEmergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s
Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency Hemostasis Testing Patients actively bleeding
More information